We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

RLIP76 in Human Serum in Adults With Rheumatologic Diseases

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00861159
Recruitment Status : Withdrawn (Study withdrawn due to lack of staffing resources and subject interest)
First Posted : March 13, 2009
Last Update Posted : January 12, 2011
Information provided by:

Study Description
Brief Summary:
It is the investigators aim to determine the feasibility of directly detecting anti-RLIP76 auto-antibodies in human serum using prepared RLIP76 antigen peptides in persons with rheumatologic disease and persons without rheumatologic diesease ("healthy subjects").

Condition or disease
Carotid Atherosclerosis

Detailed Description:
This is an exploratory study conducted to see the feasibility of measuring the anti-RLIP76 antibody and to standardize the methods for its measurement. We will perform these studies on blood samples obtained from human subjects after informed concent for blood draw for research purposes is obtained by the Clinical Research Co-ordinator (CRC).

Study Design

Study Type : Observational
Estimated Enrollment : 100 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Measurement Of RLIP76 Auto Antibodies in Human Serum In Adults With Rheumatologic Diseases.
Study Start Date : September 2011
Estimated Primary Completion Date : September 2011
Estimated Study Completion Date : September 2011
Groups and Cohorts


Outcome Measures

Primary Outcome Measures :
  1. The focus of the present study is limited to establishing validated protocols for detection of anti-RLIP76 antibodies in human sera. [ Time Frame: three years ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
The experimental populations subject to study will be 100 outpatients in the rheumatology clinic otherwise undergoing routinely scheduled phlebotomy for standard clinical care purposes.

Inclusion Criteria:

  • Adult (age 18+), non-pregnant subjects with previously diagnosed rheumatologic disease will be candidates for the study.

Exclusion Criteria:

  • Children, pregnant women, prisoner, persons with any medical condition that precludes phlebotomy, and patients unwilling or unable to provide consent.
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00861159

United States, Texas
University of North Texas Health Science Center
Fort Worth, Texas, United States, 76109
Sponsors and Collaborators
University of North Texas Health Science Center
Principal Investigator: Sanjay Awasthi, MD University of North Texas Health Science Center
More Information


Responsible Party: Measurement of RLIP76 Auto Antibodies in Human Serum in Adults with Rheumatologic Disease., University of North Texas Health Science Center
ClinicalTrials.gov Identifier: NCT00861159     History of Changes
Other Study ID Numbers: 2008-31
First Posted: March 13, 2009    Key Record Dates
Last Update Posted: January 12, 2011
Last Verified: January 2011

Keywords provided by University of North Texas Health Science Center:
RLIP76 Auto Antibodies

Additional relevant MeSH terms:
Carotid Artery Diseases
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Immunologic Factors
Physiological Effects of Drugs